|iCo Therapeutics Inc.|
760-777 Hornby Street
BC V6Z 1S4
Canada - Map
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-007, an antisense inhibitor that is in Phase II clinical trial for the treatment of diabetic macular edema; and iCo-008 (Bertilimumab), a human immunoglobulin monoclonal antibody, which is in Phase I clinical trial to treat sight threatening ocular allergies and various systemic indications. The company also develops Oral Amphotericin B Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections in immune-compromised patients, such as in HIV/AIDS, cancer, transplant recipients, diabetics, etc., as well as certain parasitical infections. iCo Therapeutics Inc. has partnership arrangements with Isis Pharmaceuticals, Inc.; MedImmune Limited; Immune Pharmaceuticals Inc.; AstraZeneca; and the University of British Columbia. iCo Therapeutics Inc. was founded in 2005 and is headquartered in Vancouver, Canada.
|Mr. Andrew J. Rae BSc, MBA,
Co-Founder, Chief Exec. officer, Pres, Director, Chairman of Governance & Nominating Committee, Member of Audit Committee and Member of Compensation Committee
|Mr. W. John Meekison B.A., C.I.M., P. Log.,
Chief Financial Officer and Corp. Sec.
|Dr. Peter Hnik M.D., M.H.Sc.,
Chief Medical Officer
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in CAD.|